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INTRODUCTION
Erythropoietin (EPO) promotes ery-
thropoiesis via ligation and homodimer-
ization of EPOR (1–3). Recent data show
that EPO is expressed in several tissues
and has multiple tissue-protective and
reparative activities, being a prototypic
tissue-protective cytokine (4,5). These
properties of EPO have been investigated
in preclinical models of ischemic, trau-
matic and inflammatory injuries and di-
verse models of vascular disease (6–8).
Injury of the vascular endothelium
represents a critical feature in the early
stages of vascular disease (9–11). Hy-
poxia is associated with endothelial in-
jury and dysfunction, and also stimulates
EPO production. In fact, EPO derived
from vascular endothelial cells appears
to be important in protecting the en-
dothelium against ischemic injury
(12–14), possibly through its effects on
endothelial cell proliferation, apoptosis
and differentiation, as well as via the in-
duction of angiogenesis (15–17).
Recent studies have shown that the
protective effects of EPO are mediated by
a tissue-protective receptor, which is dis-
tinct from the conventional homodimeric
EPOR. This tissue-protective receptor is a
heterodimeric complex composed of
EPOR and the common β subunit of re-
ceptors for GM-CSF, IL-3 and IL-5 (βCR,
also known as CD131) (9,18–21).
As a tissue-protective cytokine, EPO
has hematopoietic effects that may be
undesirable, increasing the hematocrit,
and possibly increasing the risk of car-
diovascular complications including hy-
pertension and thrombosis (22,23). A
new generation of EPO analogues that
are tissue-protective but not erythropoi-
etic have therefore been developed.
These compounds bind to the EPOR-βCR
heterodimeric complex but not the EPOR
homodimer, and therefore may represent
a potentially safer and more effective in-
tervention for the treatment of vascular
disease (12,24,25).
Carbamylated EPO (CEPO) is tissue-
protective in several models in vivo, yet
is not erythropoietic because it does not
bind to the classical homodimeric EPOR
(26). More recently, an 11-amino acids
helix B surface peptide that mimics the
tertiary structure of EPO has been devel-
oped that has tissue-protective properties
without stimulating hematopoiesis
(27,28).
EPO and its nonerythropoietic ana-
logues have been shown to be protective
in models of cardiovascular injury (29,30)
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and to promote wound healing in the
skin (27,28). The aim of this study was to
investigate the potential of EPO and its
analogues in aortic endothelial cells at
low oxygen concentrations, as these may
be particularly relevant to vascular dis-
ease, including atherosclerosis. For this
purpose, we investigated the protective
effect of EPO, CEPO and pHBSP in an in
vitro model of wound healing in bovine
aortic endothelial cells (BAECs) in low
(5%) and atmospheric (21%) oxygen con-
centrations. We also studied the effects of
EPO and its analogues on BAEC prolifer-
ation and migration, two processes that
are important in wound closure in this
model. The results reported here indicate
that oxygen concentration may be an im-
portant factor in determining susceptibil-
ity to tissue-protective cytokines.
MATERIALS AND METHODS
All chemicals were from Sigma-
Aldrich unless otherwise stated. The
peptide (pHBSP, or ARA290; pyroglu-
EQLERALNSS) and its scrambled form
(scr-pHBSP; pyroglu-LSEARNQSEL)
were from Araim Pharmaceuticals.
Cell Culture
Bovine aortic endothelial cells (BAECs)
were obtained from the European Collec-
tion of Cell Cultures (ECACC) and used
between passages 4 and 12. The cells
were cultured in Dulbecco’s Modified
Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and
penicillin/streptomycin (final concentra-
tion 100 IU/mL), and were cultured at
37°C in a humidified atmosphere con-
taining 5% CO2 and 21% oxygen.
Scratch Assay
The scratch assay was the term used
for the endothelial cell injury model. The
conditions of this model were initially
optimized by culturing the cells after in-
jury in culture media containing different
concentrations of FBS (0%, 1% and 10%)
over a period of 0, 24, 48 and 72 h. The
optimized condition of 1% FBS and a
24 h incubation were used to study the
effect of EPO and its analogues at vary-
ing concentrations (0 to 100 ng/mL)
under 21% oxygen and 5% oxygen, ei-
ther acute (24 h after injury) or chronic 
(1 wk before injury and 24 h after injury).
For the scratch assay, the cells were
seeded into 12-well plates at a seeding
density of 1 × 105 cell/mL and cultured in
normal medium until confluent. A scratch
was made in the cell monolayer using a
P1000 blue plastic pipette tip (Starlab Ltd.)
creating a cell free area of approximately
1.5-mm width. The cells were then washed
three times with PBS to remove any loose
cell debris, then medium containing 1%
FBS with or without EPO, CEPO or pHBSP
was added. A peptide with a scrambled se-
quence of amino acids (scr-pHBSP) was
used at the same concentration to ensure
that the effects of the amino acid sequence
in pHBSP were specific. The defined area
of the wound was photographed under an
inverted microscope (Olympus CKX41) at
4× magnification with a Micropix 5
megapixel color CMOS digital camera. The
position of the wound image was stan-
dardized each time against a horizontal
line drawn on the base of the plate passing
through the center of each well. All the im-
ages were quantified using ImageJ soft-
ware (NIH, rsb.info.nih.gov/ij).
Real-time qPCR
Cells were seeded into 24-well plates
and cultured until 80% confluent, at
which point one plate was incubated
under 21% oxygen while a matched plate
was incubated under 5% oxygen for 24 h
prior to RNA extraction.
Cells were lysed using TRIzol (Invitro-
gen, Life Technologies) and RNA was
then extracted and purified. RNA quality
and concentration were determined
using a NanoDrop ND-1000 (NanoDrop
Technologies) (31).
Reverse transcription and real-time
quantitative PCR (qPCR) were carried out
on RNA samples for EPOR, βCR, VEGF
and β2-microglobulin (a housekeeping
gene not affected by change in oxygen
levels), using TaqMan gene expression as-
says (Applied Biosystems/ Life Technolo-
gies) as previously reported (32). For gene
expression quantification, the compara-
tive threshold cycle (ΔΔCt) method was
used following manufacturer’s guide-
lines. Results were normalized to β2-mi-
croglobulin expression and expressed as
arbitrary units using one of the normoxic
samples as a calibrator. VEGF, a hypoxia-
induced gene, was measured as a positive
control to validate the method and condi-
tions used for the experiment.
Western Blot
BAECs were seeded into 24 well plates
at a seeding density of 1 × 105 cell/mL
and cultured until 80% confluent, at
which point one plate was incubated
under 21% oxygen while a matched plate
was incubated under 5% oxygen for 24 h.
Cells were then lysed in 80 μL lysis buffer
(25 mmol/L Tris HCl pH 7. 6, 0.1% SDS,
1% deoxycholate, 1% NP40, 0.5 mol/L
EDTA, 40 mmol/L EGTA and protease
inhibitors). Lysates were then centrifuged
at 11,000g for 15 min at 4°C and the su-
pernatant was collected. Protein concen-
trations were quantified using a BCA
reagent kit (Pierce Biotechnology). Thirty
μg of cellular proteins were separated on
a 10% SDS-polyacrylamide gel elec-
trophoresis and transferred onto a nitro-
cellulose membrane (Amersham/GE
Healthcare Life Sciences). After blocking
with 5% skimmed milk (for EPOR detec-
tion) or 3% bovine serum albumin (BSA)
for βCR detection for 1 h, membranes
were incubated with various primary 
antibodies overnight, followed by HRP-
conjugated secondary antibodies for 1 h
at room temperature. EPOR was detected
using goat anti-EPOR (W-20) (Santa Cruz
Biotechnology, Heidelberg, Germany) at
1:200 dilution and anti-goat secondary
antibody (A8919) (Sigma-Aldrich, Dorset,
UK) at 1:10,000 dilution. βCR was de-
tected using rabbit anti-βCR( N-20)
(Santa Cruz Biotechnology, Heidelberg,
Germany) at 1:200 dilution and anti-rab-
bit secondary antibody (A0545) (Sigma-
Aldrich, Dorset, UK) at 1:5,000 dilution.
GAPDH was used as a loading control
and detected using rabbit monoclonal
GAPDH antibodies (14C10) (Cell Signal-
ing Technology) at 1:1000 dilution and
anti-rabbit secondary antibody A0545
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(Sigma-Aldrich, Dorset, UK) at 1:20,000
dilution. Protein bands were visualized
by exposing membranes developed with
the ECL reagent (Amersham/GE Health-
care Life Sciences, Little Chalfont, Buck-
inghamshire, UK) to chemiluminescence
film (Hyperfilm ECL) (Amersham/GE
Healthcare Life Sciences).
Immunofluorescence
BAECs were cultured on poly-L-
 ornithine–coated coverslips until conflu-
ent. Cells were scratched and cultured
under 21% or 5% oxygen for 24 h prior to
fixation. Cells were then washed with PBS
and fixed with 4% paraformaldehyde for
15 min at room temperature. Fixed cells
were then washed with PBS and treated
with 1% Triton X-100 in PBS (Sigma-
Aldrich) for 10 min at room temperature
to permeabilize the plasma membrane.
After blocking the cells using 10% donkey
serum and 0. 3% Triton X-100 for 1 h at
room temperature, they were incubated
with goat anti-EPOR and rabbit anti-βCR
at 1:100 dilution in 1% donkey serum at
room temperature for 1 h. Donkey anti-
goat IgG-FITC (sc-2024, Santa Cruz
Biotechnology, Heidelberg, Germany) and
donkey anti-rabbit IgG-CFL 647 (sc-362291,
Santa Cruz Biotechnology, Heidelberg,
Germany) (1:100 dilution each) were the
secondary antibodies used to detect EPOR
and βCR respectively. Cellular nuclei were
stained with Prolong Gold antifade
reagent with DAPI (P36941) (Life Tech-
nologies). Images were obtained using a
confocal laser scanning microscope (Leica
TCS SP8) at 20× or 100× magnification.
Fluorescence signal was quantified by cal-
culating corrected total cell fluorescence
(CTCF). CTCF was calculated to minimize
any autofluorescence from the back-
ground using the following formula:
CTCF = Integrated density – (area of 
selected cell × mean fluorescence
of background).
Cell Viability Assay
Cell viability was evaluated using the
trypan blue exclusion method. Cells
were seeded into 96-well plates at a den-
sity of 1 × 104 cells/mL (0.15 mL/well) in
culture medium. After 24 h, medium was
removed and replaced by 150 μL fresh
medium containing different concentra-
tions of EPO, CEPO, pHBSP or scr-
pHBSP (0, 1 and 10 ng/mL) and incu-
bated for 0, 24 and 48 h. At each time
point, trypan blue was added and
stained (dead) and unstained (living)
cells were counted. Results were ex-
pressed as viable cell count/mL.
Migration Assay
A micro-Boyden chamber assay (Neu-
roProbe) was used to assess the effect of
EPO, CEPO, pHBSP and scr-pHBSP at
various concentrations (0, 0. 1, 1, and
10 ng/mL) on cell migration under 21%
or 5% oxygen using a 48-well micro Boy-
den chamber as previously described
(33). Cells were cultured under 21% or
5% oxygen for 24 h prior to the experi-
ment. Cells were allowed to migrate for 
4 h. The cells that migrated through an 
8-μm-pore-size polycarbonate, PVP-free
filter membrane were then stained using
Diff-Quick stain (Gamidor Tech Services
LTD) and counted under 40× magnifica-
tion microscope.
Statistical Analysis
All data were analyzed using GraphPad
Prism 4 software. Differences in treat-
ment (with or without EPO or its ana-
logues) were tested for significance using
one-way analysis of variance (ANOVA)
followed by a Bonferroni correction for
multiple comparisons post-test. A t test
was used to compare the expression of
EPOR or βCR under different oxygen
levels.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Low Oxygen Tension Is Required for
Stimulation of Wound Closure by EPO
and Its Analogues
After preliminary experiments testing
various conditions, EPO, CEPO and
pHBSP were used at a concentration of 
1 ng/mL in culture medium containing
1% FBS as this concentration yielded opti-
mum results after an incubation period of
24 h at 5% oxygen level. This effect was
not observed at 21% oxygen (Supplemen-
tary Figure S1). Using 10% FBS caused a
rapid and almost complete repair, and
therefore it would have been impossible
to detect a reparative action of a test com-
pound at this serum concentration.
As shown in Figure 1, EPO, CEPO and
pHBSP significantly improved scratch
closure 24 h after treatment in BAECs
cultured under acute (24 h, during the
culture with the test compound) or
chronic (1 wk preexposure) exposure to
5% oxygen. The effect of 10% FBS is
shown as a positive control. However,
EPO and its analogues showed no signif-
icant improvement on wound closure in
cells maintained in 21% oxygen. No sig-
nificant change was observed after treat-
ment with the scrambled peptide (scr-
pHBSP) under either 21% or 5% oxygen.
EPOR Expression Is Increased in BAECs
under Low Oxygen
Quantitative PCR was used to com-
pare the gene expression of EPOR and
βCR under different oxygen levels. As
shown in Figure 2, EPOR mRNA levels
were significantly increased by two-fold
in 5% oxygen, while those for βCR did
not change significantly. VEGF was used
as a positive control representing a hy-
poxia-inducible gene, and its expression
increased by six-fold under our experi-
mental conditions.
To assess the significance of the ob-
served induction of EPOR mRNA, EPOR
and βCR proteins were also studied
using immunofluorescence and Western
blot. In immunofluorescence experi-
ments, the negative control (no antibody
against the protein of interest) showed
no significant staining for EPOR (green)
or βCR (red), indicating the specificity of
the antibody used (Figure 3A). Without
changes to the settings of the confocal
microscope, to allow a direct compari-
son, we detected a strong signal for
EPOR when cells where incubated in 5%
oxygen compared with a weak signal
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when they were cultured under 21% oxy-
gen (Figure 3A). No change in the signal
for βCR expression was observed in ei-
ther 21% or 5% oxygen. Semiquantitative
image analysis of the signals showed a
significant increase in the intensities of
EPOR in hypoxia compared with nor-
moxia, but no difference in the signal in-
tensity of βCR (Figure 3B).
Western blot analysis showed a very
similar pattern for the expression of both
proteins, with EPOR protein, but not
βCR, being increased in 5% oxygen com-
pared with 21% oxygen (Figure 4).
EPO and Its Tissue-Protective
Analogues Induce BAECs Proliferation
Figure 5 shows cell proliferation (as-
sessed by counting viable cells as de-
scribed in Materials and Methods) in
cells exposed to EPO, CEPO, pHBSP or
scr-pHBSP under 21% oxygen (left panel)
or 5% oxygen (right panel). While in 21%
oxygen there was no significant change
in cell proliferation between treated and
untreated cells (Figures 5A, C, E), in 5%
oxygen, a significant proliferative effect
of EPO and its analogues was observed
after 24 h (Figures 5B, D, F). Treatment
with scr-pHBSP did not significantly in-
crease cell proliferation under any oxy-
gen concentration (Figures 5G, H). We
obtained similar results using the MTT
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Figure 1. Low oxygen tension stimulates wound closure induced by EPO and its analogues in a scratch assay model in BAECs. EPO and its
analogues (CEPO and pHBSP) enhanced wound closure in BAECs when incubated in 5% oxygen for 24 h (acute) and when incubated
in 5% oxygen for 1 wk prior to injury and 24 h after injury (chronic) but not under 21% oxygen at a concentration of 1 ng/mL. The scram-
bled peptide (scr-pHBSP) showed no effect on wound closure in BAECs under 21% and 5% oxygen. Results are expressed as % wound
healing after 24 h. Each data point represent the mean value ± SEM (n = 6), *p < 0.05, **p < 0.01, ***p < 0.01. Representative examples of
the scratch assay images with the scratch area outlined under 21% and acute 5% oxygen for untreated cells and cells treated with EPO
or its analogues are also shown (lower panel).
Figure 2. Low oxygen tension increases gene expression of EPOR but not of the β com-
mon receptor (βCR) in BAECs. Cells were cultured under 21% or 5% oxygen for 24 h, then
EPOR (A) and βCR (B) expression was analyzed by quantitative PCR (qPCR). (C) VEGF, a
known hypoxia-induced gene, was measured as a positive control. The data are ex-
pressed as arbitrary units versus the samples incubated in 21% oxygen and are expressed
as the mean ± SEM of nine samples. *p < 0.05, p** < 0.01.
assay as a different method for assessing
proliferation, based on detection of cell
metabolism (Supplementary Figure S2).
EPO and Its Tissue-Protective
Analogues Induce BAECs Migration
The possible chemotactic effect of EPO
and its analogues was studied in a stan-
dard cell migration assay using a micro-
Boyden chamber. In 21% oxygen, EPO,
CEPO and pHBSP had no significant ef-
fect on cell migration (Figure 6A) but
they stimulated cell migration in 5% oxy-
gen (Figure 6B). It can be noted from the
same figure that scr-pHBSP had no effect
under either conditions.
DISCUSSION
Several studies have demonstrated the
efficacy of tissue-protective molecules,
including EPO, CEPO and pHBSP, in
various models of wound healing such
as burn injury (34) and cutaneous punch
wound (27,35), A case report on the effect
of EPO on the healing of skin ulcers was
reported (36) and a multicenter clinical
trial is ongoing with EPO in burn and
scald injuries (37). Whilst the possible
wound healing actions of EPO have been
investigated in other contexts, most of
these studies have focused on skin
wounds and their inflammatory and mi-
crovascular complications.
Here we show that at an oxygen con-
centration of 5%, aortic endothelial cells
are more responsive to the regenerative
action of EPO than when they are main-
tained at an oxygen concentration of
21%, and this effect is shared by nonery-
thropoietic EPO derivatives or tissue-
protective peptides. Our findings may be
of relevance to the response to ischemic
injury and to vascular diseases associ-
ated with lower oxygenation. The com-
parison of the effects of EPO with its
nonerythropoietic analogues sheds light
on the mechanisms involved in the pro-
tective effects of EPO and its analogues
in the vascular endothelium. The fact
that low oxygen tension augments the re-
sponsiveness of cells to the reparative ef-
fect of EPO, at least in part via upregula-
tion of EPOR expression, is consistent
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Figure 3. Low oxygen tension increases the protein expression of EPOR but not of the 
β common receptor. (A) Immunostaining of BAECs cultured under 21% oxygen or 5% oxy-
gen (24 h incubation) with anti-EPOR and anti-βCR antibodies, which were then exam-
ined by confocal microscopy. Nuclei were stained with DAPI. Images shown are at 20×
magnification with insets representing a 100× magnification of the cells. Negative control
images represent cells that have not been treated with the antibodies against the pro-
tein of interest. Quantitative analysis of EPOR and βCR expression is shown in (B) repre-
sented as corrected total cell fluorescence (arbitrary unit). Each data point represents
the mean ± SEM (n = 3), **p < 0.01.
Figure 4. EPOR and not βCR protein expression increases in BAECs under low oxygen con-
ditions. Western blot analysis of BAECs cultured under 21% oxygen and 5% oxygen for 24 h,
showing the expression of EPOR (56 kDa) and βCR (130 kDa). GAPDH (37 kDa) was used as
loading control for the samples.
with the increased EPOR expression re-
ported in the ischemic brain (38), and
provides additional evidence supporting
the hypothesis that EPOR is implicated
in the protective action of EPO. How-
ever, the effects of CEPO in this model
indicate that the reparative actions are
not mediated by the classical EPOR ho-
modimer that is involved in the erythro-
poietic action of EPO (26). Our results
are compatible with the hypothesis that,
in some cases, tissues may not be fully
responsive to EPO due to the lack of one
of the subunits of the tissue-protective
receptor heterocomplex (7). However
they become responsive following injury
(12,39), exposure to inflammatory cy-
tokines such as tumor necrosis factor-α
(TNF-α) (40) or hypoxia (41,42), with the
expression of the EPOR subunit being a
limiting factor. This finding may recon-
cile, at least in part, the fact that EPO ex-
erts its activity (in this case, tissue pro-
tection) on other cells than erythroblasts
with the observation that EPOR expres-
sion is very low on nonerythroid cells. It
also explains the protective activity of
EPO in various models of organ hypoxia.
The effective concentration of EPO
used in our in vitro model was 1 ng/mL
(Supplementary Figure S1), a lower con-
centration than reported in some previ-
ous studies, in which a concentration
range (8 to 40 ng/mL) was used for in
vitro studies (32,43–45). One possible ex-
planation could be an increased respon-
siveness to EPO under lower oxygen
concentrations. This might be due to
the observed upregulation of EPOR in
low oxygen. However, low oxygen in-
duces several factors in addition to
EPO, including VEGF and heat shock
proteins, which, in turn, could increase
EPOR expression (40,46,47). It is there-
fore possible that low oxygen tension
induces other mediators that synergize
with EPO or its analogues by several
mechanisms. In our experimental
model, even higher concentration of
EPO, up to 100 ng/mL did not increase
healing significantly, although there was
a trend for a dose-dependent increase. It
may be that slightly different experi-
mental conditions might explain the
healing effect observed by others at at-
mospheric oxygen concentrations.
Our data also shed light on the mecha-
nisms underlying the reparative action of
tissue-protective cytokines. Several
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Figure 5. Low oxygen tension induces the effect of EPO and its tissue-protective ana-
logues on BAECs proliferation. BAECs were treated with EPO, CEPO, pHBSP and scr-pHBSP
at different concentrations (0, 1 and 10 ng/mL) then incubated under 21% oxygen (left
panel) or 5% oxygen (right panel) for 24 h. The effect of EPO (A,B), CEPO (C,D), pHBSP
(E,F) and scr-pHBSP (G,H) on BAECs proliferation was analyzed by trypan blue exclusion
method. Each data point represent mean ± SEM (n = 3), *p < 0.05 and ** p < 0.01.
mechanisms could play a role in these ef-
fects of EPO, including angiogenesis,
modulating inflammation, promoting
cell migration or proliferation, and mobi-
lizing endothelial progenitor cells. An-
giogenesis is a major physiological re-
sponse to ischemia that involves a
sequence of events including cell prolif-
eration, migration and differentiation of
ECs; it is regulated by several proangio-
genic growth factors, including VEGF,
basic fibroblast growth factor (bFGF), ni-
tric oxide (NO) and angiopoietin-1
(48,49).
In the context of vascular wound
healing and within the limitations of
the experimental model used here, EPO
might act by promoting both cell prolif-
eration and migration, which are essen-
tial for initiating therapeutic angiogene-
sis. The induction of cell proliferation
and migration in arterial endothelial
cells is in agreement with earlier re-
ports on the effects on mesenchymal
stem cells (33) and bovine aortic en-
dothelial cells (44), but these studies
did not focus on oxygen tension and its
effect on cell migration and prolifera-
tion. Other studies looked at the effect
of hypoxia on enhancing cell migration
with EPO but did not investigate the re-
sponses to the EPO analogues (50–52).
The regrowth and repair of the vascular
endothelium appears to be an impor-
tant factor limiting the accelerated ath-
erosclerosis observed in some models of
arterial injury (53).
EPO has other, potentially deleterious,
effects on the vascular endothelium, in-
cluding the induction of procoagulant or
inflammatory factors expression, such as
E- and P-selectin, plasminogen activator
inhibitor (PAI) and vascular cell adhe-
sion molecule-1 (VCAM-1). These may
contribute to the prothrombotic effects
that have been reported for EPO, and
are not observed with CEPO or the
small-molecular weight peptide pHBSP.
Of note, pHBSP has been engineered
specifically to activate the body’s natural
repair system following injury via acti-
vation of antiinflammatory, tissue-pro-
tective and reparative signaling path-
ways (7,9,26,27,54).
CONCLUSION
Our study shows the efficacy of EPO
and its analogues in promoting repair
of aortic endothelial cells primed by
low oxygen tension. These effects were
probably mediated by effects on cell mi-
gration and proliferation. Future stud-
ies using in vivo models of vascular in-
jury will determine whether EPO ana-
logues may be of value in human vas-
cular disease.
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